JULY 26, 2025 — ANOTHER ROUND OF LAYOFFS
The company has announced plans for another round of job reductions at its South San Francisco headquarters. The reduction will impact 87 employees, including technical and leadership roles, business analysts, data scientist-engineers, and several senior scientists, and commencing on September 15, 2025, with further separations continuing through January 2026. These job cuts are part of a larger workforce restructuring effort at Genentech.
JUNE 11, 2025 — 143 HQ EMPLOYEES
The company has announced a reduction in force, impacting 143 employees in its San Francisco, California, company headquarters. The lay-offs will be complete by July 14, 2025.
According to a company statement, “The success and sustained growth of our business hinges on our ability to proactively identify innovation opportunities early and adapt to a changing external environment. This requires us to allocate and sometimes shift resources judiciously to enhance operational efficiency.”
APRIL 14, 2024 — 500 LAYOFFS
It appears the company has targeted 436 headquarters employees, effective June 5, 2024.
According to a company spokesperson, “Note that this limited reduction will allow us to shift resources to the areas that we believe can provide the greatest impact for patients. We are actively hiring in a number of areas to bring forward our most promising molecules and capabilities, and we project that the overall workforce across Roche will remain stable throughout 2024.”
AUGUST 17, 2023 — 130 LAYOFFS IN VACAVILLE, CALIFORNIA
Roche’s Genentech biologics plant in Vacaville, California, has announced plans to lay off 130 employees by the end of 2023 in response to declining demand for its injected medications.
According to a company statement, “Following a detailed operational analysis, we have made the difficult decision to eliminate approximately 130 positions at our Vacaville facility by the end of the year. We are making this organizational change in response to current and anticipated production requirements, the volumes required for some of our new medicine formulations, and shift schedule adjustments.”
MARCH 28, 2023 — 265 EMPLOYEES IN SOUTH SAN FRANCISCO, CALIFORNIA
Genentech, an independent subsidiary of Roche, has announced the closure of its close its South San Francisco biotechnology drug production facility and lay off 265 employees.
A company spokesperson noted, "More than 15 years ago, we made a strategic decision to exit commercial manufacturing in South San Francisco. This decision was part of a thoughtful, long-term plan to focus clinical supply manufacturing in South San Francisco, where it is co-located with our R&D organization while moving commercial manufacturing to other sites in our global manufacturing network.”
“We deeply value and respect all of our employees and their contributions to the legacy — and future — of manufacturing here in South San Francisco. They are integral to our ability to deliver innovative medicines to those who need them, and we are committed to supporting those whose jobs have been impacted during this time."
AUGUST 10, 2022 — 130 EMPLOYEES IN VACAVILLE, CALIFORNIA
Roche has confirmed that 130 workers will be laid off in its Genentech biologics plant in Vacaville, California by year-end 2022.
According to a company spokesperson, “We are making this organizational change in response to current and anticipated production requirements, the volumes required for some of our new medicine formulations, and shift schedule adjustments. The company is committed to the continued success of our operations in Vacaville, which is our largest manufacturing facility and a vital part of the global Roche network.”
DECEMBER 22, 2021 — 52 LAYOFFS AT ROCHE PRODUCT DEVELOPMENT HUB IN SAN FRANCISCO, CALIFORNIA
Roche is continuing its cost-cutting/efficiency initiative and requiring its subsidiary, Genentech, to lay off 52 employees, including 10 management associates, the global head of the lifecycle team office, a principal global medical science director, and two program managers. Layoffs are scheduled for January 4, 2022.
According to a company statement, Genentech said it is redeploying additional resources in its product development team to "projects directly involved in developing medical advances to support the sustainable growth of our portfolio. The success and long-term growth of our business depends on our ability to respond to change, appropriately allocate resources and manage our work efficiently. We continually evaluate our operations to ensure we remain well-positioned to meet the needs of patients today and deliver on our growing pipeline of new medicines in the future."
JULY 1, 2021 — LAYOFFS ON THE HORIZON AT ROCHE
Roche is in the process of reviewing its global business and has suggested that there can be 300 - 400 layoffs in the near future.
According to a company spokesperson, “Roche is taking a close look at its organization of more than 100,000 employees in a ‘new prioritization of the work.’ No further decisions have been made at this time."
